# Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

> **NCT00558727** · PHASE1 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumors
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** RH-1

## Key facts

- **NCT ID:** NCT00558727
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558727, "Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00558727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*